APA (7th ed.) Citation

Lal, H., Poder, A., Campora, L., Geeraerts, B., Oostvogels, L., Vanden Abeele, C., & Heineman, T. C. (2018). Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine, 36(1), 148. https://doi.org/10.1016/j.vaccine.2017.11.019

Chicago Style (17th ed.) Citation

Lal, Himal, Airi Poder, Laura Campora, Brecht Geeraerts, Lidia Oostvogels, Carline Vanden Abeele, and Thomas C. Heineman. "Immunogenicity, Reactogenicity and Safety of 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Older Adults: Results of a Phase III, Randomized, Open-label, Multicenter Study." Vaccine 36, no. 1 (2018): 148. https://doi.org/10.1016/j.vaccine.2017.11.019.

MLA (9th ed.) Citation

Lal, Himal, et al. "Immunogenicity, Reactogenicity and Safety of 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Older Adults: Results of a Phase III, Randomized, Open-label, Multicenter Study." Vaccine, vol. 36, no. 1, 2018, p. 148, https://doi.org/10.1016/j.vaccine.2017.11.019.